BiotechTube

SerpinPC

Phase 2Terminated
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemophilia a

Conditions

Hemophilia a, Hemophilia B

Trial Timeline

Jul 6, 2023 → Feb 28, 2025

NCT ID
NCT05789524

About SerpinPC

SerpinPC is a phase 2 stage product being developed by Centessa Pharmaceuticals for Hemophilia a. The current trial status is terminated. This product is registered under clinical trial identifier NCT05789524. Target conditions include Hemophilia a, Hemophilia B.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT06568302Phase 3Terminated
NCT05789537Phase 2Terminated
NCT05789524Phase 2Terminated

Competing Products

20 competing products in Hemophilia a

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
77
EmicizumabChugai PharmaceuticalPhase 3
77
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
77
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
77
EmicizumabChugai PharmaceuticalPhase 3
77
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
77
EmicizumabRochePhase 3
77
HEMLIBRAJohnson & JohnsonPre-clinical
23
EmicizumabRochePhase 3
77
EmicizumabRocheApproved
85
EmicizumabRochePhase 3
77
SPK-8011QQRochePhase 1/2
41
NXT007RochePhase 1/2
41
Emicizumab InjectionRochePhase 2
52
Bypassing Agents + FVIII ReplacementRochePre-clinical
23
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
51
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
22
Refacto AFPfizerPre-clinical
22
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
76
ReFacto AFPfizerPhase 3
76

Other Products from Centessa Pharmaceuticals

SerpinPCPhase 3
72
LixivaptanPhase 3
72
LixivaptanPhase 3
72
Lixivaptan + PlaceboPhase 3
72
ORX750 + ORX750 + ORX750Phase 2
47